Adopted guidelines of care for the topical management of psoriasis from American and German guidelines  by Al Raddadi, Ali A. et al.
Journal of the Saudi Society of Dermatology & Dermatologic Surgery (2011) 15, 5–13King Saud University
Journal of the Saudi Society of Dermatology &
Dermatologic Surgery
www.ksu.edu.sa
www.jssdds.org
www.sciencedirect.comREVIEW ARTICLEAdopted guidelines of care for the topical management
of psoriasis from American and German guidelines qAli A. Al Raddadi a,*, Mohammad I. Fatani b, Yasir H. Shaikh c, Diamant Thaci d,
Abdullah A. Al Reshaid e, Abdullah M. Al-Eisa f, Walid A. Alghamdi g,
Hassan Y. Abdulfattah h, Zohir M. Al Belbisi h, Ali C. Atawi i,
Waleed A. Alajroush e, Abdullah A. Al Fadly j, Said I. El-Shamy k,
Sameer K. Zimmo l, Abdullah A. Alqahtani m, Majdy M. Abdulghani n,
Khaled M. Al Abod o, Khaled M. Al Attas p, Mohamad F. Al Ayouby q,
Mohammed S. Qari l, Adel S. Al Ghanim ra National Guard Hospital, King Abdulaziz Medical City, PO Box 9515, Jeddah 21423, Saudi Arabia
b Hera General Hospital, Makkah, Saudi Arabia
c King Fahd Specialist Hospital, PO Box 15215, Dammam 31444, Saudi Arabia
d Goethe University, Frankfurt, Senckenberganlage 3160325, Frankfurt am Main, Germanyq Developed by the guideline committee of the following members: (1)
Dr. Ali Atallah Al Raddadi, Jeddah; (2) Dr. Sameer Khader Zimmo,
Jeddah; (3) Dr. Mohammed Saleh Abdulfattah Qari, Jeddah; (4) Dr.
Majdy Mohammed Rashad Abdulghani, Jeddah; (5) Dr. Diamant
Thaci, Germany; (6) Abdullah Abdelrahman Al Reshaid, Riyadh; (7)
Dr. Abdullah Mohammed. H. Al-Eisa, Riyadh; (8) Dr. Walid Ali
Alghamdi, Riyadh; (9) Dr. Hassan Yaser N. Abdulfattah, Riyadh; (10)
Dr. Zohir Mustafa Al Belbisi, Riyadh; (11) Dr. Ali Charif Atawi,
Riyadh; (12) Dr. Waleed Ahmed S. Alajroush, Riyadh; (13) Dr.
Abdullah Abdulmohsen Al Fadly, Riyadh; (14) Dr. Said Ibrahim El-
Shamy, Riyadh; (15) Dr. Yasir Hasan Shaikh, Dammam; (16) Dr.
Adel Soliman Al Ghanim, Dammam; (17) Dr. Abdullah Aljubran
Alqahtani, Abha; (18) Dr. Mohammad Ibrahim Fatani, Makkah; (19)
Dr. Khaled Mohamed Al Abod, Makkah; (20) Dr. Khaled M. Al
Attas, Jazan; (21) Dr. Mohamad Fakhry Al Ayouby, Madinah.
* Corresponding author. Address: Dermatology Division, King
Abdulaziz Medical City, P.O. Box 9515, Jeddah 21423, Saudi Arabia.
E-mail address: aliraddadi@hotmail.com (A.A. Al Raddadi).
2210-836X ª 2010 King Saud University. Production and hosting by
Elsevier B.V. All rights reserved.
Peer review under responsibility of King Saud University.
doi:10.1016/j.jssdds.2010.10.002
Production and hosting by Elsevier
6 A.A. Al Raddadi et al.e National Guard Hospital, King Abdulaziz City, PO Box 22490, Riyadh 22490, Saudi Arabia
f Derma Clinic, Alolia - Cross of Athalatheen Street & Aldabab Street, Riyadh, Saudi Arabia
g Security Force Hospital, PO Box 3643, Riyadh 11481, Saudi Arabia
h Riyadh Medical Complex, PO Box 2897, Riyadh 11196, Saudi Arabia
i Specialized Medical Center, PO Box 66548, Riyadh 11586, Saudi Arabia
j King Faisal Specialist Hospital and Research Center, PO Box 3354, Riyadh 11211, Saudi Arabia
k National Hospital, PO Box 2715, Riyadh 11461, Saudi Arabia
l King Abdulaziz University, PO Box 80200, Jeddah 21589, Saudi Arabia
m Military Hospital, PO Box 101, Khamis Mushait, Saudi Arabia
n King Fahd Military Hospital, PO Box 9862, Jeddah 21159, Saudi Arabia
o King Faisal Hospital, Al Munhana Street, Shisha, Makkah, Saudi Arabia
p King Fahd Central Hospital, PO Box 204, Jazan, Saudi Arabia
q King Fahd Hospital, PO Box 3892, Madinah, Saudi Arabia
r King Fahd Military Medical Complex, PO Box 946, Dahran 31932, Saudi ArabiaReceived 10 June 2010; accepted 30 June 2010
Available online 15 December 2010KEYWORDS
Psoriasis;
Guidelines;
SaudiAbstract Psoriasis is a chronic, noncontiguous, inﬂammatory, multisystem disease with predomi-
nantly skin and joint manifestations affecting approximately 2% of the population. There is a
genetic predisposition to psoriasis and has tendency to wax and wane with ﬂares related to systemic
or environmental factors, including life stress events and infection.
Majority of patients with psoriasis have limited disease (5% body surface area involvement) and
can be treated with topical agents, which generally provide a high efﬁcacy-to-safety ratio.
To optimize the topical treatment of psoriasis in Saudi Arabia, the Saudi Society of Dermatology
and Dermatologic surgery (SSDDS) have initiated a project to develop guidelines for the manage-
ment of psoriasis. The guidelines are based on German and American one with subsequent discus-
sion with experts in the ﬁeld; they have been approved by a team of dermatology experts.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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psoriasis
Psoriasis is a common dermatologic disease, affecting approx-
imately 0.3–2.5% of the population (Plunkett and Marks,
1998). Plaque psoriasis is the most common form, accounting
for approximately 90% of cases. The disease is usually chronic
and persistent, although up to 50% of patients may enter
spontaneous remission for varying periods of time.Psoriasis has a signiﬁcant impact on patient quality of
life. The social and psychological impact is considerable.
Psoriasis is not considered a life-threatening disease, but it
is well established that those patients may experience a
range of psychosocial difﬁculties, including elevated levels
of anxiety, depression, and worry (Richards and Fortune,
2006).
The etiopathogenesis of psoriasis is still not fully under-
stood and involves a complex interaction of genetic and
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a keratinisation disorder, but now substantial evidence
indicates that different components of the innate- and
acquired-immunity (T cells, dendritic cells, and inﬂammatory
cytokines) are critically involved in initiating and maintaining
the inﬂammatory response (Tagami and Aiba, 1997; Jullien,
2006).
There is no cure for psoriasis; therefore, the aim of treat-
ment is to minimize the extent and severity of the disease to
the point at which it no longer substantially disrupts the pa-
tient’s quality of life (Fairhurst et al., 2005).
Topical therapy is the mainstay of treatment for mild to
moderate psoriasis and often the initial treatment for severe
psoriasis (Ashcroft et al., 2000).
About 80% of patients with psoriasis are treated topically
(Peeters et al., 2005). Patients treated with phototherapy or
systemic agents, including biological agents, can also be man-
aged with topical agents as adjunctive therapy (Guenther et al.,
2004).
First-line therapy of psoriasis usually consists of topical
agents, such as emollients, tar, dithranol, corticosteroids and
vitamin D3 analogues. In cases of severe, extensive psoriasis,
where topical therapy is either impractical or not sufﬁciently
effective, phototherapy or systemic treatment may be war-
ranted at the outset.
The majority of patients with psoriasis have limited disease
(<5% body surface area involvement) and can be treated with
topical agents, which generally provide a high efﬁcacy-to-
safety ratio.
In this guideline of care for psoriasis, we discuss the use of
topical medications for the treatment of psoriasis. We will dis-
cuss the efﬁcacy and safety as well as offer recommendations
for the use of topical corticosteroids, vitamin D analogues,
tacrolimus, pimecrolimus, salicylic acid, anthralin, coal tar,
as well as combination therapy.Table 1 Recommendations for topical corticosteroids.
Indication Plaque-type psoriasis
Initial dose 1–2 times per day
Maintenance dose Gradual reduction following onset of e
Duration of dosing – Should be initiated and monitored b
– For clobetasol and halobetasol, ma
2 weeks
Expected response After 1–2 weeks
Short-term results Highly potent agents have greater eﬃca
Long-term results – True efﬁcacy and risks associated w
duration
– Tachyphylaxis, while not demonstra
given patient
– Combination with other topical an
effects
Adverse drug reaction – Local – skin atrophy, telangiectasia
– Systemic – hypothalamic–pituitary–
in a large BSA (>30%)
Contraindication Skin infections, rosacea, perioral derma
Baseline monitoring None
Pregnancy Category C
Nursing Unknown safety
Pediatric use Because of the increased skin surface/b
systemic eﬀects secondary to enhanced
children mid-potent steroids could be s2. Method
A work group of expert dermatologists from different loca-
tions in Saudi Arabia set to determine the scope of the guide-
line and to identify best data from American Academy of
Dermatology (AAD) (Menter et al., 2009) and German guide-
line (Nast et al., 2007) and adopted it according to team expe-
rience. So we have utilized expert opinion to generate this
clinical guideline.
2.1. Before use of this guideline
This guideline is intended for dermatologists in private
and government hospitals as well as for other specialties in-
volved in the treatment of psoriasis. All physicians follow
the recommendations contained in this guideline under their
own risk.
2.2. Topical treatments for psoriasis
Topical therapy forms the cornerstone in the management of
psoriasis. Of signiﬁcant value as monotherapy in mild to mod-
erate psoriasis, it is used predominantly as adjunctive therapy
in moderate and severe forms of the disease. These are medi-
cines in creams, ointments and lotions that are applied to the
skin and scalp. There are a number of different approaches
possible. Here are some of the most common topical
treatments.
2.3. Corticosteroids
Topical steroids are the most commonly prescribed medicine
for psoriasis. They are the primary treatment strategy for most
mild to moderate cases of psoriasis.ﬀect
y dermatologists
ximal weekly use should be 25 g or less short-term treatment max.
cy than less potent agents
ith long-term use are unknown as most clinical trials are of short
ted in clinical trials, may affect the long-term results achieved in a
d variations in dosing schedules may lessen risk of long-term side
, striae, purpura, contact dermatitis, rosacea
adrenal axis suppression with high potency topical steroid and usage
titis
ody mass ratio, the risks to infants and children may be higher for
absorption. Growth retardation is also a potential concern. In
uﬃcient. Caution especially on the face.
8 A.A. Al Raddadi et al.The mechanisms of action of corticosteroids include anti-
inﬂammatory, anti proliferative, immunosuppressive, and
vasoconstrictive effects. These effects are mediated through
their binding to intracellular corticosteroid receptors and reg-
ulation of gene transcription of numerous genes, particularly
those that code for proinﬂammatory cytokines (Cornell and
Stoughton, 1985).
Topical corticosteroids come in different strengths designed
for use on different parts of the body. Stronger potency ste-
roids might be necessary for tough to treat patches of psoriasis
on the elbows or knees. Weaker formulas are good for more
sensitive skin on the face or groin.
Steroids can cause side effects, such as thinning of the skin,
changes in the skin color, bruising, and dilated blood vessels.
Occlusion may increase these side effects (Koo and Lebwohl,
1999; Pierard et al., 1989).
Recommendations for the use of topical corticosteroids are
shown in Table 1.
2.4. Vitamin D analogues
Calcipotriol is a vitamin D3 analogue that is as potent as cal-
citriol in inhibiting cell proliferation and inducing cell differen-
tiation in vitro but is at least 100 times less active than
calcitriol in its effect on calcium metabolism in rats (Binderup
and Bramm, 1988). During the last decade, calcipotriene has
emerged as an effective topical therapy for psoriasis (Kragballe
et al., 1988, 1991; Highton and Quell, 1995; Lea and Goa,
1996).
The mechanism of action of the vitamin D analogues in pso-
riasis is believed to be mediated by their binding to vitamin D
receptors, which leads to both the inhibition of keratino-
cyte proliferation and the enhancement of keratinocyte
differentiation.
Irritation is the most common adverse event associated with
calcipotriene use occurring in 15–25% of patients, it may
necessitate withdrawal of treatment (Lea and Goa, 1996).
Recommendations for the use of vitamin D analogues are
shown in Table 2.
2.5. Combination of calcipotriol/betamethasone dipropionate
ointment
This new two-compound ointment is a combination of calci-
potriol 50 lg/g and betamethasone dipropionate 0.5 mg/g inTable 2 Recommendations for vitamin D analogues.
Indication Plaque-type psoriasis
Initial dose Twice daily to aﬀected areas, maximum 30
Maintenance dose Twice daily up to 100 g/weeks for up one
Duration of dosing 6 weeks
Expected response After 1–2 weeks
Response rate 30–50% of patients demonstrated marked
Adverse drug reaction Skin irritation (reddening, itching, burning
Contraindication – Reversible elevation of serum calcium –
– Causes photosensitivity, but no contrai
Drug interaction – Drugs which elevate the calcium levels
– No concomitant use of topical salicylic
Baseline monitoring None
Pregnancy Category C
Nursing No information on excretion in breast mil
Pediatric use Appears to be safe between ages 2–14 yeara single vehicle (5% polyoxypropylene-15-stearyl ether)
achieving optimal delivery of both drugs in an active state into
the skin (Simonsen et al., 2004), without affecting each other’s
absorption (Hansen et al., 2001; Guenther, 2005) and it is sta-
ble and active for more than 2 years at room temperature
(Traulsen, 2004).
The combination of calcipotriol with a corticosteroid im-
proves efﬁcacy and decreases skin irritation. Two studies
showed that the administration of the combination of calcipot-
riol and betamethasone dipropionate for a 4-week period im-
proved keratinocyte proliferation, differentiation (Van
Rossum et al., 2001; Vissers et al., 2004), and inﬂammatory
characteristics (Vissers et al., 2004). Also this new two-
compound ointment induces a steroid-sparing effect in long-
term treatments and thereby reduces the risk of skin atrophy
and skin thickness (Traulsen and Hughes-Formella, 2003),
stretch marks, telangiectasia, rebound phenomenon, and
tachyphylaxis.
Calcipotriol/betamethasone dipropionate combination
ointment used once daily is well tolerated and more effective
in treatment of psoriasis than either active constituent used
alone (Kaufmann et al., 2002). Calcipotriol/betamethasone
dipropionate has been shown to be effective in mild- to mod-
erate psoriasis. It has been shown to be safe and effective in
the treatment of psoriasis vulgaris.
Recommendations for the use of vitamin D analogues are
shown in Table 3.
2.6. Calcineurin inhibitors
Tacrolimus ointment and pimecrolimus cream are approved in
the United States for treatment of atopic dermatitis. Tacroli-
mus and pimecrolimus are both calcineurin inhibitors and
function as immunosuppressants (Reynolds and Al-Daraji,
2002). Calcineurin inhibitors function by blocking the synthe-
sis of numerous inﬂammatory cytokines that play an impor-
tant role in the pathogenesis of psoriasis.
In the treatment of psoriasis, the topical use of tacrolimus
and pimecrolimus has promise (Ruzicka et al., 2003). How-
ever, neither medication has yet to be approved by the FDA
for this indication.
Neither tacrolimus ointment (Lazarous and Kerdel, 2002)
nor pimecrolimus (Gupta and Chow, 2003) cream appear
effective for treating plaque-type psoriasis when simply applied
as commercially available.% of the body surface
year in intermitting use
improvement to clearance of the lesions after 4–6 weeks
)
more likely to occur in patients treated with greater than 100 g/wk
ndications to combining with UVB phototherapy
(thiazide diuretics).
acid preparations (Inactivation)
k; pregnant and nursing mothers were excluded from clinical studies
s with maximum 50 g/week
Table 3 Recommendations for topical combination of calcipotriol/betamethasone dipropionate ointment.
Indication Plaque-type psoriasis
Initial dose Once daily
Maintenance dose Once daily. Maximum dose: 15 g per day, 100 g per week
Duration of dosing 4 weeks. After this period, repeated treatment with calcipotriol/betamethasone dipropionate ointment can be
initiated under medical supervision in an as needed base
Expected response 4–8 weeks
Response rate – According to one clinical trial, patients treated with topical ointment achieved an average PASI reduction
of 71.3% at week 4 of treatment. In the same clinical trial, patients achieved an average PASI reduction of
39.2%. after only one week of treatment
– A 52-week clinical practice dosage study showed 70% to 80% of patients treated with Calcipotriol/beta-
methasone dipropionate ointment monotherapy achieving clear or almost clear status with no drug-
related serious adverse events, such as HPA-axis oppression or striae when used on as-needed basis
Contraindication/
adverse drug reaction
Local: Common undesirable eﬀects are pruritus, rash and burning sensation of skin. Uncommon undesirable
eﬀects are skin pain or irritation, dermatitis, erythema, exacerbation of psoriasis, folliculitis and application
site pigmentation changes. Pustular psoriasis is a rare undesirable eﬀect
Systemic: Very rarely systemic eﬀects after local application of the ointment may appear, such as
hypercalcaemia from the calcipotriol or inhibition of the adrenal cortex from the corticosteroid
Baseline monitoring None
Pregnancy Category C
Nursing Betamethasone passes into breast milk but risk of an adverse eﬀect on the infant seems unlikely with
therapeutic doses. There are no data on the excretion of calcipotriol in breast milk. Caution should be
exercised when prescribing combining topical treatment to women who breast feed. The patient should be
instructed not to use treatment on the breast when breast feeding
Pediatric use Children and adolescents below 18: not recommended
Table 4 Recommendations for topical tacrolimus and pimecrolimus.
Indication No FDA-approved indications for psoriasis; primary indications for oﬀ-label use are for facial and
intertriginous psoriasis
Initial dose Pimecrolimus cream: 2·/day
Tacrolimus ointment: 1–2·/day (use on face start with 0.03%, later increase to 0.1%)
Maintenance dose Individualized
Duration of dosing No duration of course is speciﬁed
Expected response Within 2 weeks
Response rate – Plaque psoriasis: Not generally effective
– Intertriginous and facial psoriasis: 65% of patients treated with tacrolimus 0.1% ointment were clear or
almost clear after 8 weeks of therapy compared with 31% of patients treated with placebo; 71% of the
patients treated with pimecrolimus 0.1% cream were clear or almost clear after 8 weeks of therapy as com-
pared with 21% of patients treated with placebo
Adverse drug reaction/
contraindication
– Most common side effect for both medications is burning and itching
– There are no speciﬁc contraindications/adverse reactions for psoriasis
– A controversial lymphoma ‘‘black box’’ warning has been issued by the FDA
Drug interaction Do not combine with phototherapy
Baseline monitoring None
Pregnancy Category C
Nursing Tacrolimus and pimecrolimus are found in human milk and are not recommended for nursing mothers
Pediatric use Topical tacrolimus (0.03%) and topical pimecrolimus are approved for patients 2 years of age or older for
atopic dermatitis
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and pimecrolimus (Paul et al., 2000) more effective in treating
psoriasis, suggesting that there was a lack of penetration
through the thick psoriatic plaque. This led to the concept of
utilizing the topical calcineurin inhibitors in thinner skin areas
such as facial and intertriginous psoriasis with no evidence of
resultant skin atrophy as compared with the use of topical cor-
ticosteroids in these regions.The most common side effect for both medications is burn-
ing and itching that generally reduces with ongoing usage and
can also be mitigated by not applying immediately after bath-
ing. This side effect appears to be more signiﬁcant in patients
treated with tacrolimus ointment as compared with patients
treated with pimecrolimus cream.
Recommendations for the use of topical tacrolimus and
pimecrolimus are shown in Table 4.
Table 5 Recommendations for salicylic acid.
Indication For localized psoriatic lesions less than 10%
For hyperkeratotic area
No speciﬁc FDA indication
Initial dose 2–10% x/daily
Maintenance dose –
Duration of dosing 2–4 weeks
Expected response – Data are limited on salicylic acid used alone
– Comparator study of tacrolimus and salicylic acid versus tacrolimus alone in small study (N= 24) of pso-
riasis patients with 10% BSA revealed improved efﬁcacy with addition of salicylic acid. Comparator study
of 408 patients with moderate to severe psoriasis treated with mometasone and salicylic acid versus
mometasone alone for 3 weeks; psoriasis severity index measures erythema, indurations, and scaling
showed the combination of mometasone furoateesalicylic acid to be more effective than mometasone
furoate alone
Adverse drug reaction/
contraindication
Systemic absorption, although rare, can occur, especially when applied to more than 20% of BSA or in
patients with abnormal hepatic or renal function
Drug interaction Do notcombine salicylic acid with other salicylate drugs and also with vitamin D3 analogues
Salicylic acid decreases the efﬁcacy of UVB phototherapy because of a ﬁltering effect and should not be
used before UVB phototherapy
Baseline monitoring None
Pregnancy/nursing Appears to be a safe choice for the control of localized psoriasis in pregnancy
Pediatric use Because of greater risk of systemic absorption and toxicity, salicylic acid should be avoided in children
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Keratolytic agent Salicylic acid is the most widely used kerat-
olytic agent in psoriasis. It softens the scaly layers of psoriatic
plaques and eases their removal. It is applied to palms, soles
and scalp in concentrations of 2–10%. Salicylic acid is espe-
cially useful in combination with corticosteroids to enhance
penetration and improve clinical efﬁcacy (Federman and
Fraelish, 1999).
Salicylic acid is an irritant and, when used extensively at
high concentrations, can lead to salicylate toxicity.
Recommendations for the use salicylic acid are shown in
Table 5.
2.8. Anthralin
Anthralin[1,8-dihydroxy-9(10H)-anthracenone, dithranol] was
ﬁrst synthesized as a derivative of chrysarobin, prepared from
the araroba tree, and is an established, safe, and effective top-
ical treatment for psoriasis (Marsden et al., 1983).Table 6 Recommendations for anthralin.
Indication Psoriasis vulgaris
Initial dose – Begin with 0.5% or lower concentratio
– 1% preparation for short-contact thera
Maintenance dose Not recommended for maintenance therap
Duration of dosing 4–6 weeks
Expected response Limited placebo-controlled trial data, but
more potent topical corticosteroids or vita
Response rate After 2–3 weeks
Adverse drug reaction – Most common side effects are skin irrit
of skin irritation, it is important to avo
Contraindication – Acute erythrodermic form of psoriasis
Drug interaction Photosensitizing drugs with dithranol may
Baseline monitoring None
Pregnancy/nursing Category C
Pediatric use Use with cautionIt is one of few topical treatments to induce clearance of
psoriatic plaques, leading to a period of remission, although
its widespread use is limited by local irritation and staining.
Anthralin inhibits proliferation of mouse and human keratino-
cytes as well as psoriatic keratinocytes in vivo (Hayden et al.,
1994; Baxter and Stoughton, 1970), but its mechanism of ac-
tion in psoriasis remains incompletely understood and its
molecular target(s) are unknown.
The most common side effects of anthralin are skin irrita-
tion and staining of lesional and adjoining skin, nails, clothing,
and other objects with which patients come into contact.
Recommendations for the use of topical anthalin are shown
in Table 6.
2.9. Coal tar
Coal tar is produced by the primary condensation during cor-
bonization of coal (Gruber et al., 1970). In 1931 Goeckerman
popularised his therapy of coal tar in psoriasis (Goeckerman,
1931). Although the mechanism of action of coal tar is not welln for long term therapy
py, with increasing concentration over time as tolerated
y
as monotherapy, anthralin appears to have lower eﬃcacy than
min D derivatives
ation and staining of the skin and other touching objects. Because
id contact with surrounding normal skin
vulgaris, pustular psoriasis
increase their photosensitizing eﬀect
Table 7 Recommendations for coal tar.
Indication Used in the treatment of psoriasis for more than 100 years
Initial dose 5–20% ointments or gels for topical therapy, daily
Maintenance dose No long term application or widespread use, clinical monitoring for potential development of skin carcinoma
is required
Duration of dosing Maximum 4 weeks
Expected response After 4–8 weeks, eﬃcacy improves in combination with UV application
Response rate In double-blind, randomized, controlled trial of 324 patients with mild to moderate psoriasis comparing 1%
coal tar lotion with 5% coal tar extract, there was better improvement in both PASI score and Total Sign
Score in patients treated with 1% lotion than in 5% extract
Adverse drug reaction/
contraindication
– Often poorly tolerated by patients because of cosmetic issues, including staining of clothes and tar odor;
other potential adverse events include irritant contact dermatitis, folliculitis, and photosensitivity
– Coal tar is carcinogenic in animals, but in humans, there are no convincing data proving carcinogenicity,
and epidemiologic studies fail to show increased risk of skin cancer in patients who use coal tar
Drug interaction – Not known with topical use
– Attention should be paid to the concomitant intake of oral photosensitizing systemic drugs
Baseline monitoring None
Pregnancy/nursing Coal tar products are contraindicated during pregnancy and nursing
Pediatric use Use with caution
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ing the mitotic labeling index of keratinocytes.
Many formulations of coal tar exist, and standardization of
these products is not always ideal. In one small study of 18 pa-
tients, 5% liquor carbonis detergens was more effective than
its emollient base in the treatment of psoriasis (Kanzler and
Gorsulowsky, 1993).
Side-effects of tar include folliculitis, irritation, and photo-
sensitivity. It should not be used on acutely inﬂamed skin, or
on pustular or erythrodermic psoriasis (Comaish, 1981).
There is no deﬁnitive evidence of an increased risk of skin
cancer above the expected incidence for the general population
from the use of therapeutic tar (Pion et al., 1995; Pittelkow
et al., 1981).
Education regarding the favorable safety proﬁle and place in
therapy as a steroid-sparing adjunct may increase tolerance and
compliance of this excellent and underutilized topical therapy.
Recommendations for the use of topical Coal tar are shown
in Table 7.
2.10. Emollient
Emollient therapy describes the application of moisturisers
which are used to make the skin less scaly and dry. OftenTable 8 Recommendations for emollient.
Indication The use of emollients represents an internationally
accepted standard adjunctive therapeutic
approach to the treatment of psoriasis
Dosing Applied once to three times daily
Eﬃcacy Two controlled studies of aloe vera had conﬂicting
results
Contraindication
No known contraindications
Baseline
monitoring
None
Pregnancy/
nursing
Generally considered safe
Pediatric use Generally considered safethe words emollient and moisturiser are used interchangeably.
Emollients or moisturizers can act as an important adjunctive
therapy of topical treatment in psoriatic patients. The use of an
emollient can limit relapses after the end of corticosteroid ther-
apy, and maintain the improvement obtained after 1 month
corticosteroid therapy at clinical level (physician global assess-
ment) and skin dryness (Seite´ et al., 2009). There are numerous
other non-medicated topical moisturizer compounds and for-
mulations available; depending on the individual product, they
can be applied up to several times daily. The goal of treatment
with these agents is to provide and retain moisture in the stra-
tum corneum; these agents are thought to function by forming
a ﬁlm on the skin surface to help retain moisture. There are no
known contraindications to the use of these non-medicated
moisturizers; the large majority of these agents are considered
safe during pregnancy and lactation as well as for pediatric
use. Recommendations for the use of emollients are shown
in Table 8.3. Conclusion
Great advances have been made in the understanding of the
pathogenesis of psoriasis and this has led to the use of new
therapies for patients.
The aim of these guidelines is to help the dermatologist to
know more about different types of topical therapies and to re-
duce toxicity and side effects. Topical therapies still have a vi-
tal role to play in the management of psoriasis. The letter class
of drugs possesses better efﬁcacy and a better patient accept-
ability proﬁle.Acknowledgments
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